Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. The planned Phase Ib/2a clinical trial (IND 178511) is designed to investigate the safety, to
Related Questions
What enrollment criteria and patient population size are required for the trial, and how might that influence trial risk?
What is the anticipated timeline for enrollment and data read‑out from the Phase Ib/2a GBM trial?
How does this trial program compare to competitor pipelines targeting GBM or other CNS indications?
What potential regulatory or safety challenges could delay or jeopardize the trial’s progression?
How might the partnership or licensing structure (if any) for STAR‑001 affect future revenue streams or margin assumptions?
How will the FDA clearance for the IND affect Lantern Pharma’s short‑term stock price?
Will the trial results be disclosed in upcoming investor presentations or conference calls, and what impact could that have on market perception?
What are the projected market size and commercial upside if the combination therapy receives eventual approval?
How does STAR‑001 (LP‑184) in combination with spironolactone compare to existing GBM treatments in terms of mechanism and potential efficacy?
What is the expected cost of the Phase Ib/2a trial and its impact on Lantern Pharma’s cash runway and financing needs?